Følg
Olga H Nikolova
Olga H Nikolova
Oregon Health & Science University
Verifisert e-postadresse på acm.org - Startside
Tittel
Sitert av
Sitert av
År
The TP53 Apoptotic Network Is a Primary Mediator of Resistance to BCL2 Inhibition in AML CellsTP53 Network Mediates Resistance to BCL2 Inhibition
T Nechiporuk, SE Kurtz, O Nikolova, T Liu, CL Jones, A D'Alessandro, ...
Cancer discovery 9 (7), 910-925, 2019
1262019
An expanded universe of cancer targets
WC Hahn, JS Bader, TP Braun, A Califano, PA Clemons, BJ Druker, ...
Cell 184 (5), 1142-1155, 2021
492021
Using interdisciplinary bioinformatics undergraduate research to recruit and retain computer science students
J Beck, B Buckner, O Nikolova
ACM SIGCSE Bulletin 39 (1), 358-361, 2007
362007
Involving undergraduates in the annotation and analysis of global gene expression studies: creation of a maize shoot apical meristem expression database
B Buckner, J Beck, K Browning, A Fritz, L Grantham, E Hoxha, Z Kamvar, ...
Genetics 176 (2), 741-747, 2007
262007
Parallel globally optimal structure learning of Bayesian networks
O Nikolova, J Zola, S Aluru
Journal of Parallel and Distributed Computing 73 (8), 1039-1048, 2013
232013
Functional Precision Medicine Identifies Novel Druggable Targets and Therapeutic Options in Head and Neck CancerDruggable Target Discovery in Head and Neck Cancer
C Xu, O Nikolova, RS Basom, RM Mitchell, R Shaw, RD Moser, H Park, ...
Clinical Cancer Research 24 (12), 2828-2843, 2018
222018
The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells. Cancer Discov. 2019; 9: 910–925. doi: 10.1158/2159-8290
T Nechiporuk, SE Kurtz, O Nikolova, T Liu, CL Jones, A D’alessandro, ...
CD-19-0125.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0
22
CTD2 Dashboard: a searchable web interface to connect validated results from the Cancer Target Discovery and Development Network
BA Aksoy, V Dančík, K Smith, JN Mazerik, Z Ji, B Gross, O Nikolova, ...
Database 2017, 2017
192017
Parallel Bayesian network structure learning with application to gene networks
O Nikolova, S Aluru
SC'12: Proceedings of the International Conference on High Performance …, 2012
182012
A parallel algorithm for exact Bayesian network inference
O Nikolova, J Zola, S Aluru
2009 International Conference on High Performance Computing (HiPC), 342-349, 2009
172009
Parallel discovery of direct causal relations and markov boundaries with applications to gene networks
O Nikolova, S Aluru
2011 International Conference on Parallel Processing, 512-521, 2011
162011
Modeling Gene-Wise Dependencies Improves the Identification of Drug Response Biomarkers in Cancer Studies
O Nikolova, R Moser, C Kemp, M Gonen, AA Margolin
Bioinfromatics, 2017
102017
The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells. Cancer Discov. 2019; 9 (7): 910–925. doi: 10.1158/2159-8290
T Nechiporuk, SE Kurtz, O Nikolova, T Liu, CL Jones, A D'Alessandro, ...
CD-19-0125.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0
7
Transforming Big Data into cancer-relevant insight: An initial, multi-tier approach to assess reproducibility and relevance
Cancer Target Discovery and Development Network
Molecular Cancer Research 14 (8), 675-682, 2016
52016
The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells. Cancer Discov. 2019; 9 (7): 910–25
T Nechiporuk, SE Kurtz, O Nikolova, T Liu, CL Jones, A D'Alessandro, ...
Epub 2019/05/03. doi: 10.1158/2159-8290. CD-19-0125. PubMed PMID: 31048320, 0
5
A parallel algorithm for exact Bayesian structure discovery in Bayesian networks
Y Chen, J Tian, O Nikolova, S Aluru
arXiv preprint arXiv:1408.1664, 2014
32014
A parallel algorithm for exact structure learning of Bayesian networks
O Nikolova, J Zola, S Aluru
Neural Information Processing Systems (NIPS), 2010
22010
Associating drug sensitivity with differentiation status identifies effective combinations for acute myeloid leukemia
SE Kurtz, CA Eide, A Kaempf, N Long, D Bottomly, O Nikolova, BJ Druker, ...
Blood advances 6 (10), 3062-3067, 2022
2022
Synthetic lethal kinases in Ras/p53 mutant squamous cell carcinoma
R Moser, KE Gurley, O Nikolova, G Qin, R Joshi, E Mendez, I Shmulevich, ...
Oncogene, 1-15, 2022
2022
Associating Ex Vivo Drug Sensitivity with Differentiation Status Identifies Effective Drug Combinations for Acute Myeloid Leukemia
CA Eide, SE Kurtz, A Kaempf, N Long, D Bottomly, O Nikolova, BJ Druker, ...
Blood 138, 1301, 2021
2021
Systemet kan ikke utføre handlingen. Prøv på nytt senere.
Artikler 1–20